AbCellera is breaking the barriers of conventional antibody drug discovery to bring better medicines to patients, sooner. AbCellera’s engine integrates expert teams, technology, and facilities with the data science and automation needed to propel antibody-based medicines from target to clinic in nearly every therapeutic area with precision and speed. AbCellera provides innovative biotechs and leading pharmaceutical companies with a competitive advantage that empowers them to move quickly, reduce cost, and tackle the toughest problems in drug development.
1
Total Investments
1
Portfolio Companies
-
Exits
1
Industries
General Information
Industries
Biotechnology
Company Overview
About AbCellera
Recent Investments (1)
View All| Company | Stage | Amount | Date |
|---|---|---|---|
| Series A | •••••• | Sep 2020 |
All startup & investor data, one platform.
Filter investors by stage, sector, and geography. Compare portfolios side by side. Spot market signals before anyone else.